Drugmakers Race to Develop New Weight Loss Treatments
Pharmaceutical giants and biotech firms are advancing a new wave of oral and injectable obesity treatments to challenge the dominance of Novo Nordisk and Eli Lilly. Analysts expect annual sector sales to reach 100 billion dollars within the next decade as clinical trials show significant weight loss results.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B and ELI LILLY & CO are defending their dominance as pharmaceutical rivals race to capture a weight-loss market projected to reach $100B in annual sales. The sector is shifting toward oral therapies, with the United Kingdom recently approving a pill version of Wegovy. This transition to oral drugs and next-generation injections determines which firms will secure long-term market share in the obesity space.
